Tolura

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
22-02-2023
Produktens egenskaper Produktens egenskaper (SPC)
22-02-2023

Aktiva substanser:

Telmisartan

Tillgänglig från:

Krka, d.d., Novo mesto 

ATC-kod:

C09CA07

INN (International namn):

telmisartan

Terapeutisk grupp:

Angiotensin II antagonists, plain

Terapiområde:

Hypertension

Terapeutiska indikationer:

HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage.

Produktsammanfattning:

Revision: 11

Bemyndigande status:

Authorised

Tillstånd datum:

2010-06-04

Bipacksedel

                                44
B. PACKAGE LEAFLET
45
PACKAGE LEAFLET: INFORMATION FOR THE USER
TOLURA 40 MG TABLETS
telmisartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Tolura is and what it is used for
2.
What you need to know before you take Tolura
3.
How to take Tolura
4.
Possible side effects
5.
How to store Tolura
6.
Contents of the pack and other information
1.
WHAT TOLURA IS AND WHAT IT IS USED FOR
Tolura belongs to a class of medicines known as angiotensin II
receptor antagonists. Angiotensin II is
a substance produced in your body which causes your blood vessels to
narrow, thus increasing your
blood pressure. Tolura blocks the effect of angiotensin II so that the
blood vessels relax, and your
blood pressure is lowered.
TOLURA IS USED TO treat essential hypertension (high blood pressure)
in adults. ‘Essential’ means that
the high blood pressure is not caused by any other condition.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead
sometimes to heart attack, heart or kidney failure, stroke, or
blindness. There are usually no symptoms
of high blood pressure before damage occurs. Thus it is important to
regularly measure blood pressure
to verify if it is within the normal range.
TOLURA IS ALSO USED TO reduce cardiovascular events (i.e. heart attack
or stroke) in adults who are at
risk because they have a reduced or blocked blood supply to the heart
or legs, or have had a stroke or
have high risk diabetes. Your doctor can tell you if you are at high
risk for su
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Tolura 40 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 40 mg telmisartan.
Excipients with known effect:
Each tablet contains 149.8 mg sorbitol (E420) and 57 mg lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
40 mg: white to almost white, biconvex, oval tablets
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Hypertension
Treatment of essential hypertension in adults.
Cardiovascular prevention
Reduction of cardiovascular morbidity in adults with:
-
manifest atherothrombotic cardiovascular disease (history of coronary
heart disease, stroke, or
peripheral arterial disease) or
-
type 2 diabetes mellitus with documented target organ damage.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Treatment of essential hypertension
The usually effective dose is 40 mg once daily. Some patients may
already benefit at a daily dose of
20 mg. In cases where the target blood pressure is not achieved, the
dose of telmisartan can be
increased to a maximum of 80 mg once daily. Alternatively, telmisartan
may be used in combination
with thiazide-type diuretics such as hydrochlorothiazide, which has
been shown to have an additive
blood pressure lowering effect with telmisartan. When considering
raising the dose, it must be borne
in mind that the maximum antihypertensive effect is generally attained
four to eight weeks after the
start of treatment (see section 5.1).
Cardiovascular prevention
The recommended dose is 80 mg once daily. It is not known whether
doses lower than 80 mg of
telmisartan are effective in reducing cardiovascular morbidity.
When initiating telmisartan therapy for the reduction of
cardiovascular morbidity, close monitoring of
blood pressure is recommended, and if appropriate adjustment of
medications that lower blood
pressure may be necessary.
3
_Special populations_
Patients with renal impairment
Limited experience is available in patients with severe renal
impai
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 22-02-2023
Produktens egenskaper Produktens egenskaper bulgariska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 21-07-2013
Bipacksedel Bipacksedel spanska 22-02-2023
Produktens egenskaper Produktens egenskaper spanska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 21-07-2013
Bipacksedel Bipacksedel tjeckiska 22-02-2023
Produktens egenskaper Produktens egenskaper tjeckiska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 21-07-2013
Bipacksedel Bipacksedel danska 22-02-2023
Produktens egenskaper Produktens egenskaper danska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 21-07-2013
Bipacksedel Bipacksedel tyska 22-02-2023
Produktens egenskaper Produktens egenskaper tyska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 21-07-2013
Bipacksedel Bipacksedel estniska 22-02-2023
Produktens egenskaper Produktens egenskaper estniska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 21-07-2013
Bipacksedel Bipacksedel grekiska 22-02-2023
Produktens egenskaper Produktens egenskaper grekiska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 21-07-2013
Bipacksedel Bipacksedel franska 22-02-2023
Produktens egenskaper Produktens egenskaper franska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 21-07-2013
Bipacksedel Bipacksedel italienska 22-02-2023
Produktens egenskaper Produktens egenskaper italienska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 21-07-2013
Bipacksedel Bipacksedel lettiska 22-02-2023
Produktens egenskaper Produktens egenskaper lettiska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 21-07-2013
Bipacksedel Bipacksedel litauiska 22-02-2023
Produktens egenskaper Produktens egenskaper litauiska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 21-07-2013
Bipacksedel Bipacksedel ungerska 22-02-2023
Produktens egenskaper Produktens egenskaper ungerska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 21-07-2013
Bipacksedel Bipacksedel maltesiska 22-02-2023
Produktens egenskaper Produktens egenskaper maltesiska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 21-07-2013
Bipacksedel Bipacksedel nederländska 22-02-2023
Produktens egenskaper Produktens egenskaper nederländska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 21-07-2013
Bipacksedel Bipacksedel polska 22-02-2023
Produktens egenskaper Produktens egenskaper polska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 21-07-2013
Bipacksedel Bipacksedel portugisiska 22-02-2023
Produktens egenskaper Produktens egenskaper portugisiska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 21-07-2013
Bipacksedel Bipacksedel rumänska 22-02-2023
Produktens egenskaper Produktens egenskaper rumänska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 21-07-2013
Bipacksedel Bipacksedel slovakiska 22-02-2023
Produktens egenskaper Produktens egenskaper slovakiska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 21-07-2013
Bipacksedel Bipacksedel slovenska 22-02-2023
Produktens egenskaper Produktens egenskaper slovenska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 21-07-2013
Bipacksedel Bipacksedel finska 22-02-2023
Produktens egenskaper Produktens egenskaper finska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 21-07-2013
Bipacksedel Bipacksedel svenska 22-02-2023
Produktens egenskaper Produktens egenskaper svenska 22-02-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 21-07-2013
Bipacksedel Bipacksedel norska 22-02-2023
Produktens egenskaper Produktens egenskaper norska 22-02-2023
Bipacksedel Bipacksedel isländska 22-02-2023
Produktens egenskaper Produktens egenskaper isländska 22-02-2023
Bipacksedel Bipacksedel kroatiska 22-02-2023
Produktens egenskaper Produktens egenskaper kroatiska 22-02-2023

Sök varningar relaterade till denna produkt

Visa dokumenthistorik